Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase

Authors:

Abstract
No abstract available
Funding Information
  • Merck & Co., Inc.

This publication has 16 references indexed in Scilit: